{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:36:36Z","timestamp":1791279396907,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for selected patients with acute myeloid leukemia. Yet, the influence of total body irradiation (TBI)-based conditioning as compared to non-TBI-based conditioning on long-term mortality is unclear. We retrospectively evaluated outcomes after TBI-based (<jats:italic>n<\/jats:italic>\u2009=\u200991) and non-TBI-based conditioning (melphalan-based, <jats:italic>n<\/jats:italic>\u2009=\u2009248) for 1st allo-HSCT patients transplanted at the University Hospital Regensburg between 1999 and 2020. TBI was performed with an average dose rate of 4\u00a0cGy\/min. Median follow-up was 8.3\u00a0years (interquartile range, 4.8\u201312.9\u00a0years). Cumulative incidence rates of 5-year non-relapse mortality (NRM) were 17% (95% confidence interval, CI, 10\u201325) and 33% (95% CI, 27\u201340) after TBI- and non-TBI-based conditioning (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Five-year cumulative incidences of relapse (CIR) were 42% (95% CI, 32\u201352) and 29% (95% CI, 23\u201335) after TBI- and non-TBI-based conditioning (<jats:italic>P<\/jats:italic>\u2009=\u20090.030). The 5-year OS was 54% (95% CI, 43\u201364) and 55% (95% CI, 48\u201362) after TBI- and non-TBI-based conditioning. Both groups had similar 100-day acute graft-versus-host disease (aGVHD, 43% vs. 40%) and 5-year chronic GVHD (34% vs. 36%). The multivariable regression models found no associations of TBI with the outcomes NRM, CIR, PFS, OS, aGVHD, and cGVHD. TBI was no risk factor for NRM, even including mortality caused by secondary malignancies. NRM was influenced by patient age, advanced disease status, and the use of female donors for male recipients. TBI- and non-TBI-based conditioning appear to be equally effective and tolerable for AML patients eligible for 1st allo-HSCT.<\/jats:p>","DOI":"10.1007\/s00277-023-05318-y","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T08:19:17Z","timestamp":1687421957000},"page":"2199-2211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-9337","authenticated-orcid":false,"given":"Isabella","family":"Gruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Koelbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Treutwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"issue":"13","key":"5318_CR1","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","volume":"98","author":"G Soci\u00e9","year":"2001","unstructured":"Soci\u00e9 G, Clift RA, Biaise D, Devergie A, Ringden O, Martin PJ, Remberger M, Joachim Deeg H, Ruutu T, Michallet M, Sullivan KM, Chevret S (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98(13):3569\u20133574. https:\/\/doi.org\/10.1182\/blood.V98.13.3569","journal-title":"Blood"},{"issue":"12","key":"5318_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15(12):1628\u20131633. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"5318_CR3","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"4","key":"5318_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"5318_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-016-0658-y","volume":"11","author":"PM H\u00e4rtl","year":"2016","unstructured":"H\u00e4rtl PM, Treutwein M, Hautmann MG, M\u00e4rz M, Pohl F, K\u00f6lbl O, Dobler B (2016) Total body irradiation-an attachment free sweeping beam technique. Radiat Oncol 11:1\u20138. https:\/\/doi.org\/10.1186\/s13014-016-0658-y","journal-title":"Radiat Oncol"},{"issue":"3","key":"5318_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 21(3):389-401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"5318_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/J.BBMT.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD et al (2005) National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11(12):945\u2013956. https:\/\/doi.org\/10.1016\/J.BBMT.2005.09.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5318_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S et al (2021) Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27(8):642\u2013649. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.007","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"5318_CR9","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.bbmt.2015.05.019","volume":"21","author":"T Hahn","year":"2015","unstructured":"Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ, Yan L, Liu S, Spellman S, Tritchler D, Clay A, Onel K, Pasquini M, McCarthy PL (2015) Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 21(9):1679\u20131686. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5318_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/03610918.2018.1476697","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen J, Hou Y, Chen Z (2020) Statistical inference methods for cumulative incidence function curves at a fixed point in time. Commun Stat Simul Comput 49(1):79\u201394. https:\/\/doi.org\/10.1080\/03610918.2018.1476697","journal-title":"Commun Stat Simul Comput"},{"issue":"28","key":"5318_CR11","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M (2013) Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-a report from the acute leukemia workin. J Clin Oncol 31(28):3549\u20133556. https:\/\/doi.org\/10.1200\/JCO.2013.48.8114","journal-title":"J Clin Oncol"},{"issue":"11","key":"5318_CR12","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.bbmt.2018.07.007","volume":"24","author":"T Heinicke","year":"2018","unstructured":"Heinicke T, Labopin M, Schmid C, Polge E, Soci\u00e9 G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A (2018) Reduced relapse incidence with FLAMSA\u2013RIC compared with busulfan\/fludarabine for acute myelogenous leukemia patients in first or second complete remission: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24(11):2224\u20132232. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"5318_CR13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/S41375-019-0671-X","volume":"34","author":"LM Morsink","year":"2020","unstructured":"Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek MB, Deeg HJ, Schoch G, Appelbaum FR, Walter RB (2020) Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia 34(6):1701\u20131705. https:\/\/doi.org\/10.1038\/S41375-019-0671-X","journal-title":"Leukemia"},{"issue":"9","key":"5318_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornh\u00e4user M, Einsele H, Kolb HJ et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855\u2013864. https:\/\/doi.org\/10.1016\/S1470-2045(09)70225-6","journal-title":"Lancet Oncol"},{"issue":"17","key":"5318_CR15","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, Gorin NC, Labopin M, Nagler A, Schmid C, Mohty M (2014) Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the acute leukemia working party of the european group for blood and marrow transplantation. Cancer 120(17):2760\u20132765. https:\/\/doi.org\/10.1002\/cncr.28768","journal-title":"Cancer"},{"issue":"11","key":"5318_CR16","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/sj.bjc.6601751","volume":"90","author":"SA Carruthers","year":"2004","unstructured":"Carruthers SA, Wallington MM (2004) Total body irradiation and pneumonitis risk: a review of outcomes. Br J Cancer 90(11):2080\u20132084. https:\/\/doi.org\/10.1038\/sj.bjc.6601751","journal-title":"Br J Cancer"},{"issue":"1","key":"5318_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-018-1116-9","volume":"13","author":"DY Kim","year":"2018","unstructured":"Kim DY, Kim IH, Yoon SS, Kang HJ, Shin HY, Kang HC (2018) Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation. Radiat Oncol 13(1):1\u20139. https:\/\/doi.org\/10.1186\/s13014-018-1116-9","journal-title":"Radiat Oncol"},{"issue":"3","key":"5318_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","volume":"12","author":"JYC Wong","year":"2006","unstructured":"Wong JYC, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J, Essensten M, Forman S, Somlo G (2006) Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant 12(3):306\u2013315. https:\/\/doi.org\/10.1016\/j.bbmt.2005.10.026","journal-title":"Biol Blood Marrow Transplant"},{"key":"5318_CR19","doi-asserted-by":"publisher","unstructured":"Salhotra A, Stein AS (2022) Role of radiation based conditioning regimens in patients with high-risk aml undergoing allogenic transplantation in remission or active disease and mechanisms of post transplant relapse. Front Oncol 12:802648. https:\/\/doi.org\/10.3389\/fonc.2022.802648","DOI":"10.3389\/fonc.2022.802648"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05318-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:07:21Z","timestamp":1689232041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5318"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05318-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"16 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the local Ethics Board of the University of Regensburg (Ethics approval number 20\u20131810-101). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Daniel Wolff received honoraria from Neovii and Medac. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}